Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezatapopt DDI Study in Advanced Solid Tumors with TP53 Y220C Mutation
NCT07372625Phase 1Recruiting
- Sponsor
- PMV Pharmaceuticals, Inc.
- Start
- Feb 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rezatapopt in solid tumor (advanced stage), sponsored by PMV Pharmaceuticals, Inc. Primary endpoints: Metformin Cmax geometric mean ratio, Rosuvastatin Cmax geometric mean ratio and 16 more. Started Feb 2026; status: recruiting.
02
Drugs
rezatapopt
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07372625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07372625.